Achille Lazzarato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Achille Lazzarato has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
- Giulia Santo
Department of Nuclear Medicine, Medical University of Innsbruck, Innsbruck, Austria
3 shared publications - Francesco Dondi
Nuclear Medicine, ASST Spedali Civili di Brescia and University of Brescia, 25123 Brescia, Italy
2 shared publications Alberto Miceli
Nuclear Medicine Unit, Azienda Ospedaliera SS. Antonio E Biagio E Cesare Arrigo, Alessandria, Italy
1 shared publication- Alberto Miceli
Nuclear Medicine Unit, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e Cesare Arrigo, 15121 Alessandria, Italy
1 shared publication - Alessandra Argiolas
Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy
1 shared publication - Andrea Marongiu
Unit of Nuclear Medicine, Department of Medicine, Surgery and Pharmacy, University of Sassari, Viale San Pietro 8, 07100 Sassari, Italy
1 shared publication
Latest Publications
- Open Access
- 11 January 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 32-41
Emerging Role of [18F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results
Fluorine-18 fluorodeoxyglucose ([18F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors that are infiltrated by macrophages and other inflammatory cells. In this context, 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) has been shown to be a promising imaging biomarker of hematological malignant cell proliferation. In this review, a total of 15 papers were reviewed to collect literature data regarding the clinical application of [18F]FLT PET/CT in hematological malignancies. This imaging modality seems to be a suitable tool for noninvasive assessment of tumor grading, also showing a correlation with Ki-67 immunostaining. Moreover, [18F]FLT PET/CT demonstrated high sensitivity in detecting aggressive lymphoma lesions, especially when applying a standardized uptake value (SUV) cutoff of 3. At baseline, the potential of [18F]FLT imaging as a predictive tool is demonstrated by the low tracer uptake in patients with a complete response. However, its use is limited in evaluating bone diseases due to its high physiological uptake in bone marrow. Interim [18F]FLT PET/CT (iFLT) has the potential to identify high-risk patients with greater precision than [18F]FDG PET/CT, optimizing risk-adapted therapy strategies. Moreover, [18F]FLT uptake showed a greater ability to differentiate tumor from inflammation compared to [18F]FDG, allowing the reduction of false-positive findings and making the first one a more selective tracer. Finally, FLT emerges as a superior independent predictor of PFS and OS compared to FDG and ensures a reliable early response assessment with greater accuracy and predictive value.
- 11 January 2024
- Published by MDPI AG in Hematology Reports
- Vol. 16 (1) , 32-41
Open AccessEmerging Role of [18F]FLT PET/CT in Lymphoid Malignancies: A Review of Clinical Results
Fluorine-18 fluorodeoxyglucose ([18F]FDG) is nowadays the leading positron emission tomography (PET) tracer for routine clinical work-ups in hematological malignancies; however, it is limited by false positive findings. Notably, false positives can occur in inflammatory and infective cases or in necrotic tumors that are infiltrated by macrophages and other inflammatory cells. In this context, 3′-deoxy-3′-[18F]fluorothymidine ([18F]FLT) has been shown to be a promising imaging biomarker of hematological malignant cell proliferation. In this review, a total of 15 papers were reviewed to collect literature data regarding the clinical application of [18F]FLT PET/CT in hematological malignancies. This imaging modality seems to be a suitable tool for noninvasive assessment of tumor grading, also showing a correlation with Ki-67 immunostaining. Moreover, [18F]FLT PET/CT demonstrated high sensitivity in detecting aggressive lymphoma lesions, especially when applying a standardized uptake value (SUV) cutoff of 3. At baseline, the potential of [18F]FLT imaging as a predictive tool is demonstrated by the low tracer uptake in patients with a complete response. However, its use is limited in evaluating bone diseases due to its high physiological uptake in bone marrow. Interim [18F]FLT PET/CT (iFLT) has the potential to identify high-risk patients with greater precision than [18F]FDG PET/CT, optimizing risk-adapted therapy strategies. Moreover, [18F]FLT uptake showed a greater ability to differentiate tumor from inflammation compared to [18F]FDG, allowing the reduction of false-positive findings and making the first one a more selective tracer. Finally, FLT emerges as a superior independent predictor of PFS and OS compared to FDG and ensures a reliable early response assessment with greater accuracy and predictive value.
- Open Access
- 26 August 2023
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (1) , 99-107
Clinicians’ perspectives on PET/CT in oncological patients: an Italian National Survey
Introduction: The present web-based national survey aims to assess the clinician's perspective toward (1) the indications to perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) the utility of the interaction with the referring nuclear medicine physician, and (3) their perception of the clarity, usefulness, and the impact of the PET/CT report. Methods: We conducted a prospective web-based survey consisting of 31 multiple-choice questions and an open-text field. The questionnaire was administered to Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams and the values were expressed as numbers (percentages). Results: A total of 373 physicians completed the questionnaire. Among the 360 responses finally included in the analysis, the majority came from radiation oncologists (46%), followed by oncologists. For half of the respondents (53%), indications to perform PET/CT examination were “often” clear and easily accessible, but only 16% considered them “absolutely” clear and accessible. Additionally, most respondents (43%) considered “absolutely” necessary to facilitate access to PET/CT indications and their update. The interaction with the referring nuclear medicine physician was generally useful and satisfying. Regarding the nuclear medicine report, 74% considered “absolutely” useful to standardize the report structure, and the presence of semi-quantitative parameters was considered of great importance. Finally, in about half of the cases (53%), PET/CT report impacts patient management with major changes. Conclusion: To sum up, a “still not” complete confidence with PET/CT indications and the need to facilitate access to indications and their update emerged from our results. Moreover, a structured PET/CT report with a clarification on essential PET features is warranted. In this scenario, the participation of nuclear medicine physicians in guideline oncological committees, national and international oncological conferences as well as continuous training among all specialists involved in cancer patients’ management could be effective strategies to resolve clinicians' concerns about PET/CT, thereby improving the management of cancer patients.
- 26 August 2023
- Published by Springer Nature in Clinical and Translational Imaging
- Vol. 12 (1) , 99-107
Open AccessClinicians’ perspectives on PET/CT in oncological patients: an Italian National Survey
Introduction: The present web-based national survey aims to assess the clinician's perspective toward (1) the indications to perform positron emission tomography/computed tomography (PET/CT) in cancer patients, (2) the utility of the interaction with the referring nuclear medicine physician, and (3) their perception of the clarity, usefulness, and the impact of the PET/CT report. Methods: We conducted a prospective web-based survey consisting of 31 multiple-choice questions and an open-text field. The questionnaire was administered to Italian clinicians or surgeons who managed oncological patients. Data were analyzed using standard diagrams and the values were expressed as numbers (percentages). Results: A total of 373 physicians completed the questionnaire. Among the 360 responses finally included in the analysis, the majority came from radiation oncologists (46%), followed by oncologists. For half of the respondents (53%), indications to perform PET/CT examination were “often” clear and easily accessible, but only 16% considered them “absolutely” clear and accessible. Additionally, most respondents (43%) considered “absolutely” necessary to facilitate access to PET/CT indications and their update. The interaction with the referring nuclear medicine physician was generally useful and satisfying. Regarding the nuclear medicine report, 74% considered “absolutely” useful to standardize the report structure, and the presence of semi-quantitative parameters was considered of great importance. Finally, in about half of the cases (53%), PET/CT report impacts patient management with major changes. Conclusion: To sum up, a “still not” complete confidence with PET/CT indications and the need to facilitate access to indications and their update emerged from our results. Moreover, a structured PET/CT report with a clarification on essential PET features is warranted. In this scenario, the participation of nuclear medicine physicians in guideline oncological committees, national and international oncological conferences as well as continuous training among all specialists involved in cancer patients’ management could be effective strategies to resolve clinicians' concerns about PET/CT, thereby improving the management of cancer patients.
- Open Access
PET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score
Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[18F]fluorodeoxyglucose ([18F]FDG) imaging in oncology. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[18F]FDG PET response criteria. Results: The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions. Conclusions: available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are needed to clearly evaluate their impact on patient management.
Open AccessPET Criteria by Cancer Type from Imaging Interpretation to Treatment Response Assessment: Beyond FDG PET Score
Background: in recent years, the role of positron emission tomography (PET) and PET/computed tomography (PET/CT) has emerged as a reliable diagnostic tool in a wide variety of pathological conditions. This review aims to collect and review PET criteria developed for interpretation and treatment response assessment in cases of non-[18F]fluorodeoxyglucose ([18F]FDG) imaging in oncology. Methods: A wide literature search of the PubMed/MEDLINE, Scopus and Google Scholar databases was made to find relevant published articles about non-[18F]FDG PET response criteria. Results: The comprehensive computer literature search revealed 183 articles. On reviewing the titles and abstracts, 149 articles were excluded because the reported data were not within the field of interest. Finally, 34 articles were selected and retrieved in full-text versions. Conclusions: available criteria are a promising tool for the interpretation of non-FDG PET scans, but also to assess the response to therapy and therefore to predict the prognosis. However, oriented clinical trials are needed to clearly evaluate their impact on patient management.
- Open Access
- 7 October 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (10) , 2425
Differential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers
Purpose: We evaluate the ability of Artificial Intelligence with automatic classification methods applied to semi-quantitative data from brain 18F-FDG PET/CT to improve the differential diagnosis between Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Procedures: We retrospectively analyzed a total of 150 consecutive patients who underwent diagnostic evaluation for suspected AD (n = 67) or MCI (n = 83). All patients received brain 18F-FDG PET/CT according to the international guidelines, and images were analyzed both Qualitatively (QL) and Quantitatively (QN), the latter by a fully automated post-processing software that produced a z score metabolic map of 25 anatomically different cortical regions. A subset of n = 122 cases with a confirmed diagnosis of AD (n = 53) or MDI (n = 69) by 18–24-month clinical follow-up was finally included in the study. Univariate analysis and three automated classification models (classification tree –ClT-, ridge classifier –RC- and linear Support Vector Machine –lSVM-) were considered to estimate the ability of the z scores to discriminate between AD and MCI cases in. Results: The univariate analysis returned 14 areas where the z scores were significantly different between AD and MCI groups, and the classification accuracy ranged between 74.59% and 76.23%, with ClT and RC providing the best results. The best classification strategy consisted of one single split with a cut-off value of ≈ −2.0 on the z score from temporal lateral left area: cases below this threshold were classified as AD and those above the threshold as MCI. Conclusions: Our findings confirm the usefulness of brain 18F-FDG PET/CT QL and QN analyses in differentiating AD from MCI. Moreover, the combined use of automated classifications models can improve the diagnostic process since its use allows identification of a specific hypometabolic area involved in AD cases in respect to MCI. This data improves the traditional 18F-FDG PET/CT image interpretation and the diagnostic assessment of cognitive disorders.
- 7 October 2022
- Published by MDPI AG in Diagnostics
- Vol. 12 (10) , 2425
Open AccessDifferential Diagnosis of Alzheimer Disease vs. Mild Cognitive Impairment Based on Left Temporal Lateral Lobe Hypomethabolism on 18F-FDG PET/CT and Automated Classifiers
Purpose: We evaluate the ability of Artificial Intelligence with automatic classification methods applied to semi-quantitative data from brain 18F-FDG PET/CT to improve the differential diagnosis between Alzheimer Disease (AD) and Mild Cognitive Impairment (MCI). Procedures: We retrospectively analyzed a total of 150 consecutive patients who underwent diagnostic evaluation for suspected AD (n = 67) or MCI (n = 83). All patients received brain 18F-FDG PET/CT according to the international guidelines, and images were analyzed both Qualitatively (QL) and Quantitatively (QN), the latter by a fully automated post-processing software that produced a z score metabolic map of 25 anatomically different cortical regions. A subset of n = 122 cases with a confirmed diagnosis of AD (n = 53) or MDI (n = 69) by 18–24-month clinical follow-up was finally included in the study. Univariate analysis and three automated classification models (classification tree –ClT-, ridge classifier –RC- and linear Support Vector Machine –lSVM-) were considered to estimate the ability of the z scores to discriminate between AD and MCI cases in. Results: The univariate analysis returned 14 areas where the z scores were significantly different between AD and MCI groups, and the classification accuracy ranged between 74.59% and 76.23%, with ClT and RC providing the best results. The best classification strategy consisted of one single split with a cut-off value of ≈ −2.0 on the z score from temporal lateral left area: cases below this threshold were classified as AD and those above the threshold as MCI. Conclusions: Our findings confirm the usefulness of brain 18F-FDG PET/CT QL and QN analyses in differentiating AD from MCI. Moreover, the combined use of automated classifications models can improve the diagnostic process since its use allows identification of a specific hypometabolic area involved in AD cases in respect to MCI. This data improves the traditional 18F-FDG PET/CT image interpretation and the diagnostic assessment of cognitive disorders.
- Open Access
- 19 December 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (1) , 50
Pulmonary Function and CT Scan Imaging at Low-Level Occupational Exposureto Asbestos
Background: In spite of the reduced exposure level, and its ban in numerous countries, compensation claims for asbestos-related diseases are far from decreasing. Methods: We used retrospective exposure assessment techniques to explore respiratory function and a computerized tomography (CT) scan in relation to past asbestos exposure in 115 male workers retired from an acrylic and polyester fiber plant. Based, on detailed information on exposure circumstances, we reconstructed a cumulative exposure estimate for each patient. Results: Time-weighted average exposure in our study population was 0.24 fibers/ml (95% confidence inteval (CI) 0.19–0.29), and the average cumulative exposure was 4.51 fibers/mL-years (95% CI 3.95–5.07). Exposure was elevated among maintenance workers, compared to other jobs (p = 0.00001). Respiratory function parameters did not vary in relation to the exposure estimates, nor to CT scan results. Risk of interstitial fibrosis showed a significant upward trend (Wald test for trend = 2.62, p = 0.009) with cumulative exposure to asbestos; risk associated with 5.26 fibers/mL-years or more, was 8-fold (95% CI 1.18–54.5). Conclusions: Our results suggest that a CT scan can detect pleuro-parenchymal lung alterations at asbestos exposure levels lower than previously thought, in absence of respiratory impairment. Further studies are required to validate our techniques of retrospective assessment of asbestos exposure.
- 19 December 2019
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (1) , 50
Open AccessPulmonary Function and CT Scan Imaging at Low-Level Occupational Exposureto Asbestos
Background: In spite of the reduced exposure level, and its ban in numerous countries, compensation claims for asbestos-related diseases are far from decreasing. Methods: We used retrospective exposure assessment techniques to explore respiratory function and a computerized tomography (CT) scan in relation to past asbestos exposure in 115 male workers retired from an acrylic and polyester fiber plant. Based, on detailed information on exposure circumstances, we reconstructed a cumulative exposure estimate for each patient. Results: Time-weighted average exposure in our study population was 0.24 fibers/ml (95% confidence inteval (CI) 0.19–0.29), and the average cumulative exposure was 4.51 fibers/mL-years (95% CI 3.95–5.07). Exposure was elevated among maintenance workers, compared to other jobs (p = 0.00001). Respiratory function parameters did not vary in relation to the exposure estimates, nor to CT scan results. Risk of interstitial fibrosis showed a significant upward trend (Wald test for trend = 2.62, p = 0.009) with cumulative exposure to asbestos; risk associated with 5.26 fibers/mL-years or more, was 8-fold (95% CI 1.18–54.5). Conclusions: Our results suggest that a CT scan can detect pleuro-parenchymal lung alterations at asbestos exposure levels lower than previously thought, in absence of respiratory impairment. Further studies are required to validate our techniques of retrospective assessment of asbestos exposure.